Form D · Biotechnology
RECOMBINETICS, INC
St. Paul, MN · CIK 0001543926
Offering snapshot reported Feb 1, 2019 · SEC filing
- Reported sold
- $7.68M Offering amount: $27.6M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 20, 2016 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 1, 2019 | Amendment | $7,684,275 | $0vs Jan 11, 2018 | 11 | SEC filing |
| Sep 18, 2018 | Initial | $33,510,969 | No comparison | 14 | SEC filing |
| Mar 8, 2018 | Amendment | $6,361,560 | $4,220,409vs Jan 10, 2018 | 47 | SEC filing |
| Jan 11, 2018 | Amendment | $7,684,275 | $701,775vs Apr 27, 2017 | 11 | SEC filing |
| Jan 10, 2018 | Amendment | $2,141,151 | $2,058,651vs Oct 2, 2017 | 35 | SEC filing |
| Oct 2, 2017 | Initial | $82,500 | No comparison | 1 | SEC filing |
| Apr 27, 2017 | Initial | $6,982,500 | No comparison | 10 | SEC filing |
| Aug 23, 2016 | Initial | $630,000 | No comparison | 7 | SEC filing |
| Jul 8, 2016 | Amendment | $5,663,165 | $2,892,915vs Nov 20, 2015 | 89 | SEC filing |
| Nov 20, 2015 | Initial | $2,770,250 | No comparison | 54 | SEC filing |
| Oct 30, 2014 | Initial | $540,800 | No comparison | 25 | SEC filing |
| Aug 6, 2013 | Initial | $35,000 | No comparison | 125 | SEC filing |
| Mar 14, 2013 | Initial | $330,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-285638
The offering is complete. Total amount sold is amended and restated notes, incl accrued interest. Total remaining to be sold is $19,919,726 that will only be rec'd upon the exercise of warrants with exercise prices ranging from $5.00 to $5.50sh.
The underlying offering is complete and this amendment to the original Form D covers only the outstanding common stock issuable upon exercise of warrants sold in the underlying offering.
Source: Form D, filed Feb 1, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Aberle | Executive |
| Mitch Abrahamsen | Director |
| Mitchell Abrahamsen, Ph.D. | Executive |
| Mitchell Abramhamsen, Ph.D. | Executive |
| Jerry Arndt | Director |
| John Burtis | Executive |
| John F. Cameron | Executive |
| Daniel F. Carlson, Ph.D. | Executive |
| Kyle Dawley | Executive |
| Scott C. Fahrenkrug | Director, Executive |
| Scott C. Fahrenkrug, Ph.D. | Director, Promoter |
| Bill Farrell | Director |
| Ian R. Friendly | Director, Executive |
| Perry B. Hacket, Ph.D. | Director |
| Perry B. Hackett, Ph.D. | Director |
| Peter Hajas | Director |
| Cliff Hoffman | Director |
| Douglas Keeth | Director |
| Jim Kilman | Director |
| Wendell King | Director |
| Mark Kroll, Ph.D. | Director |
| Tammy Lee | Executive |
| William Mc Knight, Jr. | Director |
| Greg Melsen | Director |
| Paul Olson | Director |
| Paul Olson, Ed.D. | Director |
| Scott Rathgaber | Director |
| Tad Sonstegard, Ph.D. | Executive |
| Tammy Lee Stanoch | Executive |
| Tammy Lee Stanock | Executive |
| Robert Switz | Director |
| Mark Walton, Ph.D. | Executive |
| Justin Zenanko | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:St. Paul, MN, 55104